TR-1: Standard form for notification of major holdings
LONDON, 25 August 2017 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the fast-growing multinational pharmaceuticals group, announces as follows:
NOTIFICATION OF MAJOR HOLDINGS
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
Hikma Pharmaceuticals PLC
2. Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
YES
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the
notification obligation:
Vanguard Health Care Fund
4. Full name of shareholder(s) (if different from 3.):
5. Date of the transaction and date on
which the threshold is crossed or
reached:
22 August 2017
6. Date on which issuer notified:
24 August 2017
7. Threshold(s) that is/are crossed or
reached:
3%
8. Notified details:
A: Voting rights attached to shares
Class/type of
shares
if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights
Direct
Direct
Indirect
Direct
Indirect
GB00B0LCW083
7,186,729
7,186,729
7,284,981
7,284,981
3.03%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date
Exercise/
Conversion Period
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
N/A
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date
Exercise/
Conversion period
Number of voting rights instrument refers to
% of voting rights
N/A
Nominal
Delta
Total (A+B+C)
Number of voting rights
Percentage of voting rights
7,284,981
3.03%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
N/A
Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease
to hold:
12. Date on which proxy holder will cease to hold
voting rights:
13. Additional information:
14. Contact name:
Vanguard Health Care Fund
c/o The Vanguard Group, Inc.
Vanguard_Fund_Compliance@Vanguard.com
15. Contact telephone number:
+001 (610) 669-8989
Hikma Pharmaceuticals plc published this content on 25 August 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 August 2017 07:47:02 UTC.
Original documenthttp://otp.investis.com/clients/uk/hikma/rns/regulatory-story.aspx?cid=167&newsid=911493
Public permalinkhttp://www.publicnow.com/view/B303D7485F0185011075189D222028C5A6280F00
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).